463 related articles for article (PubMed ID: 16538870)
1. Ex vivo analysis of dialysis effluent-derived mesothelial cells as an approach to unveiling the mechanism of peritoneal membrane failure.
López-Cabrera M; Aguilera A; Aroeira LS; Ramírez-Huesca M; Pérez-Lozano ML; Jiménez-Heffernan JA; Bajo MA; del Peso G; Sánchez-Tomero JA; Selgas R
Perit Dial Int; 2006; 26(1):26-34. PubMed ID: 16538870
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor.
Aroeira LS; Aguilera A; Selgas R; Ramírez-Huesca M; Pérez-Lozano ML; Cirugeda A; Bajo MA; del Peso G; Sánchez-Tomero JA; Jiménez-Heffernan JA; López-Cabrera M
Am J Kidney Dis; 2005 Nov; 46(5):938-48. PubMed ID: 16253736
[TBL] [Abstract][Full Text] [Related]
3. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions.
Aroeira LS; Aguilera A; Sánchez-Tomero JA; Bajo MA; del Peso G; Jiménez-Heffernan JA; Selgas R; López-Cabrera M
J Am Soc Nephrol; 2007 Jul; 18(7):2004-13. PubMed ID: 17568021
[TBL] [Abstract][Full Text] [Related]
4. Update on mechanisms of ultrafiltration failure.
Kim YL
Perit Dial Int; 2009 Feb; 29 Suppl 2():S123-7. PubMed ID: 19270200
[TBL] [Abstract][Full Text] [Related]
5. Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients.
Aguilera A; Yáñez-Mo M; Selgas R; Sánchez-Madrid F; López-Cabrera M
Curr Opin Investig Drugs; 2005 Mar; 6(3):262-8. PubMed ID: 15816502
[TBL] [Abstract][Full Text] [Related]
6. PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage.
Sandoval P; Loureiro J; González-Mateo G; Pérez-Lozano ML; Maldonado-Rodríguez A; Sánchez-Tomero JA; Mendoza L; Santamaría B; Ortiz A; Ruíz-Ortega M; Selgas R; Martín P; Sánchez-Madrid F; Aguilera A; López-Cabrera M
Lab Invest; 2010 Oct; 90(10):1517-32. PubMed ID: 20531289
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport.
Del Peso G; Jiménez-Heffernan JA; Bajo MA; Aroeira LS; Aguilera A; Fernández-Perpén A; Cirugeda A; Castro MJ; de Gracia R; Sánchez-Villanueva R; Sánchez-Tomero JA; López-Cabrera M; Selgas R
Kidney Int Suppl; 2008 Apr; (108):S26-33. PubMed ID: 18379544
[TBL] [Abstract][Full Text] [Related]
8. WNT signaling is required for peritoneal membrane angiogenesis.
Padwal M; Cheng G; Liu L; Boivin F; Gangji AS; Brimble KS; Bridgewater D; Margetts PJ
Am J Physiol Renal Physiol; 2018 Jun; 314(6):F1036-F1045. PubMed ID: 29363326
[TBL] [Abstract][Full Text] [Related]
9. [Selected indices of peritoneal fibrosis in patients undergoing peritoneal dialysis].
Penar J; Weyde W; Krajewska M; Madziarska K; Gołebiowski T; Szymczak M; Kłak R; Klinger M
Postepy Hig Med Dosw (Online); 2009 Apr; 63():200-4. PubMed ID: 19502680
[TBL] [Abstract][Full Text] [Related]
10. Long-term intervention with heparins in a rat model of peritoneal dialysis.
Schilte MN; Loureiro J; Keuning ED; ter Wee PM; Celie JW; Beelen RH; van den Born J
Perit Dial Int; 2009; 29(1):26-35. PubMed ID: 19164250
[TBL] [Abstract][Full Text] [Related]
11. TGF-β1-VEGF-A pathway induces neoangiogenesis with peritoneal fibrosis in patients undergoing peritoneal dialysis.
Kariya T; Nishimura H; Mizuno M; Suzuki Y; Matsukawa Y; Sakata F; Maruyama S; Takei Y; Ito Y
Am J Physiol Renal Physiol; 2018 Feb; 314(2):F167-F180. PubMed ID: 28978530
[TBL] [Abstract][Full Text] [Related]
12. The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis.
Fan YP; Hsia CC; Tseng KW; Liao CK; Fu TW; Ko TL; Chiu MM; Shih YH; Huang PY; Chiang YC; Yang CC; Fu YS
Stem Cells Transl Med; 2016 Feb; 5(2):235-47. PubMed ID: 26718649
[TBL] [Abstract][Full Text] [Related]
13. Mediators of inflammation and fibrosis.
Lai KN; Tang SC; Leung JC
Perit Dial Int; 2007 Jun; 27 Suppl 2():S65-71. PubMed ID: 17556333
[TBL] [Abstract][Full Text] [Related]
14. The effect of fibrosis on peritoneal transport.
Flessner MF
Contrib Nephrol; 2006; 150():174-180. PubMed ID: 16721008
[TBL] [Abstract][Full Text] [Related]
15. The renin-angiotensin-aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum?
Nessim SJ; Perl J; Bargman JM
Kidney Int; 2010 Jul; 78(1):23-8. PubMed ID: 20336052
[TBL] [Abstract][Full Text] [Related]
16. Gremlin promotes peritoneal membrane injury in an experimental mouse model and is associated with increased solute transport in peritoneal dialysis patients.
Siddique I; Curran SP; Ghayur A; Liu L; Shi W; Hoff CM; Gangji AS; Brimble KS; Margetts PJ
Am J Pathol; 2014 Nov; 184(11):2976-84. PubMed ID: 25194662
[TBL] [Abstract][Full Text] [Related]
17. Biocompatible Dialysis Solutions Preserve Peritoneal Mesothelial Cell and Vessel Wall Integrity. A Case-Control Study on Human Biopsies.
del Peso G; Jiménez-Heffernan JA; Selgas R; Remón C; Ossorio M; Fernández-Perpén A; Sánchez-Tomero JA; Cirugeda A; de Sousa E; Sandoval P; Díaz R; López-Cabrera M; Bajo MA
Perit Dial Int; 2016; 36(2):129-34. PubMed ID: 26475848
[TBL] [Abstract][Full Text] [Related]
18. Nebivolol, a β1-adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis.
Liappas G; González-Mateo G; Aguirre AR; Abensur H; Albar-Vizcaino P; Parra EG; Sandoval P; Ramírez LG; Del Peso G; Acedo JM; Bajo MA; Selgas R; Sánchez Tomero JA; López-Cabrera M; Aguilera A
Oncotarget; 2016 May; 7(21):30133-46. PubMed ID: 27102153
[TBL] [Abstract][Full Text] [Related]
19. Autophagy promotes fibrosis and apoptosis in the peritoneum during long-term peritoneal dialysis.
Wu J; Xing C; Zhang L; Mao H; Chen X; Liang M; Wang F; Ren H; Cui H; Jiang A; Wang Z; Zou M; Ji Y
J Cell Mol Med; 2018 Feb; 22(2):1190-1201. PubMed ID: 29077259
[TBL] [Abstract][Full Text] [Related]
20. IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis.
Marchant V; Tejera-Muñoz A; Marquez-Expósito L; Rayego-Mateos S; Rodrigues-Diez RR; Tejedor L; Santos-Sanchez L; Egido J; Ortiz A; Valdivielso JM; Fraser DJ; López-Cabrera M; Selgas R; Ruiz-Ortega M
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 32987705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
